Trials / Terminated
TerminatedNCT04789408
Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1 Open-label, Multicenter Study Evaluating the Safety of KITE-222, an Autologous Anti-CLL-1 CAR T-cell Therapy, in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Kite, A Gilead Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical study is to learn more about the safety and dosing of the study drug, KITE-222, in participants with relapsed/refractory (r/r) acute myeloid leukemia (AML).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cyclophosphamide | Administered intravenously |
| DRUG | Fludarabine | Administered intravenously |
| BIOLOGICAL | KITE-222 | A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously |
Timeline
- Start date
- 2021-07-19
- Primary completion
- 2024-05-18
- Completion
- 2024-05-18
- First posted
- 2021-03-09
- Last updated
- 2025-07-11
- Results posted
- 2025-07-11
Locations
9 sites across 2 countries: United States, France
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04789408. Inclusion in this directory is not an endorsement.